
<http://bio2rdf.org/drugbank:DB00078> a <http://schema.org/Drug> ;
	<http://schema.org/name> "Ibritumomab" ;
	<http://schema.org/description> "Indium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each." ;
	<http://schema.org/url> "http://bio2rdf.org/drugbank:DB00078" ;
	<http://schema.org/clinicalPharmacology> "Ibritumomab is a murine monoclonal antibody against CD20 that has been radiolabeled with yttrium-90." ;
	<http://schema.org/cost> <http://bio2rdf.org/drugbank_resource:d142d3fd24116c4a57fc7ecaac8d4f3e> , <http://bio2rdf.org/drugbank_resource:d17f3e51cf6f5e3dad7d547f6d3c0410> ;
	<http://schema.org/interactingDrug> "DDI between Ibritumomab and Prasugrel - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Sulodexide - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Naproxen - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Levomilnacipran - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Anagrelide - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Nadroparin - Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Oxaprozin - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Tiaprofenic acid - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Citalopram - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Rivaroxaban - Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Sipuleucel-T - Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T." , "DDI between Ibritumomab and Meloxicam - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Venlafaxine - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Enoxaparin - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Natalizumab - Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased." , "DDI between Ibritumomab and Belimumab - Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab." , "DDI between Ibritumomab and Ketorolac - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Tolmetin - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Pimecrolimus - May enhance the adverse/toxic effect of Immunosuppressants." , "DDI between Ibritumomab and Phenindione - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Ticlopidine - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Fondaparinux sodium - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Abciximab and Ibritumomab - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Ethyl biscoumacetate - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Nabumetone - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Clopidogrel - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Dalteparin - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Escitalopram - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Cilostazol - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Vorapaxar - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Indomethacin - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Piroxicam - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Fluoxetine - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Trastuzumab and Ibritumomab - May enhance the neutropenic effect of Immunosuppressants." , "DDI between Ibritumomab and Edetic Acid - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Roflumilast - May enhance the immunosuppressive effect of Immunosuppressants." , "DDI between Ibritumomab and Heparin - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Bivalirudin and Ibritumomab - Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Danaparoid - Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Ibuprofen - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Tinzaparin - Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Treprostinil - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Leflunomide - Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased." , "DDI between Ibritumomab and Sertraline - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Tirofiban - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Milnacipran - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Fluvoxamine - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Sulindac - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Denosumab - May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased." , "DDI between Ibritumomab and Ticagrelor - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Acetylsalicylic acid - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Apixaban - Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Dicoumarol - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Duloxetine - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Dipyridamole - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Dabigatran etexilate - Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Floctafenine - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Citric Acid - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Warfarin - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Mefenamic acid - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Desvenlafaxine - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Acenocoumarol - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Argatroban - Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Vilazodone - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Diflunisal - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Paroxetine - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Phenprocoumon - May enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding." , "DDI between Ibritumomab and Etodolac - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Eptifibatide and Ibritumomab - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Clozapine - Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased." , "DDI between Ibritumomab and Ketoprofen - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." , "DDI between Ibritumomab and Tofacitinib - Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib." , "DDI between Ibritumomab and Fenoprofen - Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding." ;
	<http://schema.org/legalStatus> "Approved" ;
	<http://schema.org/mechanismOfAction> "The Fab segment of the antibody targets the CD20 epitope on B-cells, allowing the radioactive yttrium to destroy the cell via production of beta particles." ;
	<http://schema.org/nonProprietaryName> "radiolabeled murine anti-CD20" , "Ig gamma-2A chain C region, membrane-bound form" ;
	<http://schema.org/identifier> "drugbank:DB00078" ;
	<http://schema.org/sameAs> <http://www.drugs.com/cdi/ibritumomab-tiuxetan-with-indium-111.html> , <http://www.rxlist.com/cgi/generic3/zevalin.htm> , <http://www.drugbank.ca/drugs/DB00078> .

<http://bio2rdf.org/drugbank_resource:d142d3fd24116c4a57fc7ecaac8d4f3e> a <http://schema.org/DrugCost> ;
	<http://schema.org/costPerUnit> "4200.0" ;
	<http://schema.org/costCurrency> "USD" ;
	<http://schema.org/drugUnit> "Zevalin in-111 kit" .

<http://bio2rdf.org/drugbank_resource:d17f3e51cf6f5e3dad7d547f6d3c0410> a <http://schema.org/DrugCost> ;
	<http://schema.org/costPerUnit> "37800.0" ;
	<http://schema.org/costCurrency> "USD" ;
	<http://schema.org/drugUnit> "Zevalin y-90 kit" .
